Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023

Rhea-AI Summary

Anavex Life Sciences Corp. (Nasdaq: AVXL) will release its financial results for the quarter ending December 31, 2022, on February 7, 2023. A conference call will take place at 8:30 am ET the same day to review these results and discuss the company's growth strategy. Anavex focuses on therapeutics for neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, highlighting its lead drug candidate, ANAVEX®2-73, which has completed Phase 2 clinical trials for Alzheimer's disease. Interested parties can join the call via the webcast on the company’s website.

Positive

• ANAVEX®2-73 successfully completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease.
• The company is actively developing therapeutics for multiple CNS disorders.

Negative

• None.

Webcast and Conference Call To be Held Tuesday, February 7, 2023, 8:30 am ET

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its quarter ended December 31, 2022 on Tuesday February 7, 2023.

Management will host a conference call on Tuesday February 7, 2023, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session.

Webcast / Conference Call Information:

Management will host a conference call on Tuesday February 7, 2023, at 8:30 am ET. The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.

The conference call can be also accessed by dialing 1-305-224-1968 for participants in the U.S. using the Meeting ID# 891 9995 1143 and reference passcode 511901. A replay of the conference call will also be available on Anavex’s website for up to 30 days.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX^®2-73 (blarcamesine), has successfully completed a Phase 2a and recently a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson's disease. ANAVEX^®3-71, which targets sigma-1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations

Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

What are the financial results announcement details for Anavex Life Sciences Corp. (AVXL)?

Anavex will announce its financial results for Q4 2022 on February 7, 2023, at 8:30 am ET.

What is the significance of the upcoming conference call for AVXL?

The conference call will review financial results and provide updates on Anavex’s growth strategy.

Which drug candidate is Anavex Life Sciences focusing on for Alzheimer's disease?

Anavex is focusing on ANAVEX®2-73, which has completed several clinical trials for Alzheimer's disease.